Renfu Pharmaceutical announced that Renfu Pharmaceutical Co., Ltd., a wholly-owned subsidiary, recently received the “Drug Registration Certificate” for ethyl eicosapentaenoate softgels approved and issued by the State Drug Administration. This medication is used to reduce triglyceride levels in adult patients with severe hypertriglyceridemia on the basis of a controlled diet. It is used in combination with statins to diagnose cardiovascular disease or diabetes with at least 2 other cardiovascular disease risk factors, and in adult patients with hypertriglyceridemia to reduce the risk of cardiovascular events.

Zhitongcaijing · 09/02/2025 09:01
Renfu Pharmaceutical announced that Renfu Pharmaceutical Co., Ltd., a wholly-owned subsidiary, recently received the “Drug Registration Certificate” for ethyl eicosapentaenoate softgels approved and issued by the State Drug Administration. This medication is used to reduce triglyceride levels in adult patients with severe hypertriglyceridemia on the basis of a controlled diet. It is used in combination with statins to diagnose cardiovascular disease or diabetes with at least 2 other cardiovascular disease risk factors, and in adult patients with hypertriglyceridemia to reduce the risk of cardiovascular events.